quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·648d
PRRelease
Oncternal Therapeutics Inc. logo

Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

ONCT· Oncternal Therapeutics Inc.
Health Care
Original source

Companies

  • ONCT
    Oncternal Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Feb 24UpdateBTIG$5.00
  • Feb 24UpdateBTIG$50.00

Related

  • PR297d
    Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations
  • PR379d
    Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
  • PR412d
    Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
  • SEC515d
    Oncternal Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • SEC525d
    Oncternal Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update
  • SEC533d
    SEC Form 10-Q filed by Oncternal Therapeutics Inc.
  • PR549d
    Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
  • SEC588d
    Oncternal Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022